Overview

Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed
Trial end date:
2008-12-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of the cfor the first time in mild to moderate COPD patients.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
6-((3-((dimethylamino)carbonyl)phenyl)sulfonyl)-8-methyl-4-((3-methyloxyphenyl)amino)-3-quinolinecarboxamide